Claritas Pharmaceuticals Inc V.CLAS.H

Hey terd(s) why do bash the reason your still on the planet?

[Dude51]

2020-06-09 06:11 PT - News Release

Mr. Robert Farrell reports

KALYTERA ANNOUNCES DATA FROM STUDY IN RATS DEMONSTRATING PROOF OF CONCEPT FOR R-107 IN COVID-19 ASSOCIATED PAH

Proof of concept data in PAH were strongly positive, with R-107 preserving vascular function and restoring normal pulmonary arterial blood pressure in rats. These data demonstrated a return of pulmonary arterial blood pressure to normal baseline within 20 minutes after dosing with R-107, with no adverse impact on heart rate or peripheral arterial blood pressure. This extraordinary improvement was sustained for the full period of four hours of observation after dosing. Treatment with R-107 was not associated with apparent side effects: R-107 did not lower peripheral arterial blood pressure and it had no effect on heart rate. Taken together, these data signify that R-107 selectively lowered PAH and did not compromise peripheral hemodynamics. These preclinical findings are significantly superior in both their potency and duration of activity compared to results of currently marketed agents evaluated in the same animal models of PAH.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a severe, chronic syndrome affecting the small pulmonary arteries (blood vessels which carry blood from the heart to the lungs to pick up oxygen).
FYI Covid is not a fan of the lungs. Were still on the right road, flatening the terds that we run over on our way to BoomTown....GLTA